CL2014002406A1 - Metodo para el tratamiento de la depresion refractaria o resistente al taratamiento que comprende administrar esketamina por via intravenosa o intranasal sola o en combinacion con uno o mas antidepresivos; composicion farmaceutica; y su uso en el tratamiento de la depresion refractaria o resistente al tratamiento. - Google Patents
Metodo para el tratamiento de la depresion refractaria o resistente al taratamiento que comprende administrar esketamina por via intravenosa o intranasal sola o en combinacion con uno o mas antidepresivos; composicion farmaceutica; y su uso en el tratamiento de la depresion refractaria o resistente al tratamiento.Info
- Publication number
- CL2014002406A1 CL2014002406A1 CL2014002406A CL2014002406A CL2014002406A1 CL 2014002406 A1 CL2014002406 A1 CL 2014002406A1 CL 2014002406 A CL2014002406 A CL 2014002406A CL 2014002406 A CL2014002406 A CL 2014002406A CL 2014002406 A1 CL2014002406 A1 CL 2014002406A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- refractory
- depression
- resistant
- antidepressants
- Prior art date
Links
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 title 2
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 title 1
- 239000000935 antidepressant agent Substances 0.000 title 1
- 229940005513 antidepressants Drugs 0.000 title 1
- 229960000450 esketamine Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261609641P | 2012-03-12 | 2012-03-12 | |
| US201261610058P | 2012-03-13 | 2012-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002406A1 true CL2014002406A1 (es) | 2015-01-09 |
Family
ID=47913632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002406A CL2014002406A1 (es) | 2012-03-12 | 2014-09-11 | Metodo para el tratamiento de la depresion refractaria o resistente al taratamiento que comprende administrar esketamina por via intravenosa o intranasal sola o en combinacion con uno o mas antidepresivos; composicion farmaceutica; y su uso en el tratamiento de la depresion refractaria o resistente al tratamiento. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20130236573A1 (es) |
| KR (1) | KR20140136982A (es) |
| CN (1) | CN104519878A (es) |
| CL (1) | CL2014002406A1 (es) |
| CO (1) | CO7071129A2 (es) |
| CR (1) | CR20140410A (es) |
| GT (1) | GT201400191A (es) |
| HK (1) | HK1209323A1 (es) |
| MX (1) | MX2014010939A (es) |
| NI (1) | NI201400104A (es) |
| PE (1) | PE20141906A1 (es) |
| PH (1) | PH12014501997A1 (es) |
| SG (1) | SG11201405530SA (es) |
| WO (1) | WO2013138322A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10583138B2 (en) | 2012-07-12 | 2020-03-10 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| DK2983787T3 (da) * | 2013-04-12 | 2020-01-06 | Icahn School Med Mount Sinai | Fremgangsmåde til behandling af posttraumatisk stresssygdom |
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| EP3094312B1 (en) * | 2014-01-14 | 2019-03-13 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| PL3287124T3 (pl) | 2014-04-17 | 2023-02-20 | Ketabon Gmbh | Doustna postać dawkowania ketaminy |
| KR20170013890A (ko) * | 2014-05-06 | 2017-02-07 | 노쓰웨스턴유니버시티 | Nmdar 조절 화합물의 조합물 |
| KR20170040800A (ko) * | 2014-08-13 | 2017-04-13 | 얀센 파마슈티카 엔.브이. | 우울증 치료 방법 |
| AU2015318123A1 (en) * | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| WO2016109427A1 (en) * | 2014-12-31 | 2016-07-07 | Icahn School Of Medicine At Mount Sinai | Method of maintaining the anti-depressant effect of ketamine with lithium |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| WO2016172672A1 (en) * | 2015-04-24 | 2016-10-27 | Icahn School Of Medicine At Mount Sinai | Method for treating suicidal ideation |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| CN106562952B (zh) * | 2015-10-09 | 2020-06-09 | 江阴安博生物医药有限公司 | 氯胺酮在治疗重性抑郁障碍中的应用 |
| US11110070B2 (en) | 2015-11-17 | 2021-09-07 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| AU2017351437B2 (en) * | 2016-10-27 | 2022-01-27 | National University Corporation Chiba University | Application of (S)-norketamine and salt thereof as pharmaceutical |
| WO2018234568A2 (en) * | 2017-06-23 | 2018-12-27 | Develco Pharma Schweiz Ag | HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| WO2019094757A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| CN107823195A (zh) * | 2017-11-24 | 2018-03-23 | 无锡市精神卫生中心 | R‑氯胺酮在抑郁症急性期治疗中的应用 |
| KR20240011237A (ko) * | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2019213551A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| BR112020023882A2 (pt) * | 2018-06-27 | 2021-02-09 | Clexio Biosciences Ltd. | método para tratar transtorno depressivo maior |
| WO2020027344A1 (en) * | 2018-08-03 | 2020-02-06 | Takeda Pharmaceutical Company Limited | Ch24h inhibitors for mdd use |
| EP3628313B1 (en) | 2018-09-28 | 2025-02-12 | Novohale Therapeutics, LLC | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| AU2020223284A1 (en) * | 2019-02-17 | 2021-09-16 | Neurawell Therapeutics | Compositions and methods for treatment of depression and other disorders |
| JP2022524008A (ja) * | 2019-03-05 | 2022-04-27 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | うつ病の治療のためのエスケタミン |
| US12589083B2 (en) * | 2019-05-07 | 2026-03-31 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| CN113905777B (zh) | 2019-05-31 | 2025-06-20 | 赛隆制药股份公司 | 用于电子监督胃肠外施用药物组合物的吸入器 |
| US20220230723A1 (en) | 2019-05-31 | 2022-07-21 | Celon Pharma S.A. | Electronically Supervised Administration of a Pharmaceutical Composition |
| CN114286674A (zh) * | 2019-08-28 | 2022-04-05 | 杨森制药公司 | 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮 |
| JP2022548233A (ja) * | 2019-09-13 | 2022-11-17 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | エスケタミンの鼻腔内投与 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| JP7840873B2 (ja) * | 2020-05-28 | 2026-04-06 | ヤンセン ファーマシューティカ エヌ．ベー． | うつ病の治療方法 |
| US12233165B2 (en) | 2020-08-18 | 2025-02-25 | Oakwood Laboratories, Llc | Microsphere formulations comprising ketamine and methods for making and using the same |
| CN114681407A (zh) * | 2020-12-30 | 2022-07-01 | 北京万全德众医药生物技术有限公司 | 一种盐酸艾司氯胺酮颗粒剂 |
| JP2025087929A (ja) * | 2022-02-22 | 2025-06-11 | 国立大学法人京都大学 | うつ病および／またはうつ状態の治療および／または予防用医薬 |
| WO2025057111A1 (en) * | 2023-09-12 | 2025-03-20 | Clexio Biosciences Ltd. | Esketamine or a pharmaceutical salt thereof for use in a method of treating major depressive disorder |
| CN120919140A (zh) * | 2025-09-09 | 2025-11-11 | 徐州百瑞麻醉科技研究院有限公司 | 一种艾司氯胺酮与米氮平协同的抗抑郁药物组合物及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6176242B1 (en) * | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| EP1103256A1 (de) * | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| CA2529857A1 (en) * | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| AU2007229866A1 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20090306137A1 (en) * | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| DE102007009888A1 (de) * | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| US20110038807A1 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| EP2992877A1 (en) * | 2010-06-15 | 2016-03-09 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
-
2013
- 2013-03-12 WO PCT/US2013/030476 patent/WO2013138322A1/en not_active Ceased
- 2013-03-12 KR KR1020147028246A patent/KR20140136982A/ko not_active Ceased
- 2013-03-12 CN CN201380013908.XA patent/CN104519878A/zh active Pending
- 2013-03-12 HK HK15110013.5A patent/HK1209323A1/xx unknown
- 2013-03-12 PE PE2014001406A patent/PE20141906A1/es not_active Application Discontinuation
- 2013-03-12 MX MX2014010939A patent/MX2014010939A/es unknown
- 2013-03-12 US US13/795,454 patent/US20130236573A1/en not_active Abandoned
- 2013-03-12 SG SG11201405530SA patent/SG11201405530SA/en unknown
- 2013-12-05 US US14/098,498 patent/US20140093592A1/en not_active Abandoned
-
2014
- 2014-09-04 CR CR20140410A patent/CR20140410A/es unknown
- 2014-09-08 PH PH12014501997A patent/PH12014501997A1/en unknown
- 2014-09-10 NI NI201400104A patent/NI201400104A/es unknown
- 2014-09-10 CO CO14200330A patent/CO7071129A2/es unknown
- 2014-09-11 CL CL2014002406A patent/CL2014002406A1/es unknown
- 2014-09-11 GT GT201400191A patent/GT201400191A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO7071129A2 (es) | 2014-09-30 |
| PE20141906A1 (es) | 2014-12-05 |
| NI201400104A (es) | 2016-11-30 |
| MX2014010939A (es) | 2014-11-13 |
| HK1209323A1 (en) | 2016-04-01 |
| SG11201405530SA (en) | 2014-11-27 |
| CR20140410A (es) | 2014-11-17 |
| US20140093592A1 (en) | 2014-04-03 |
| US20130236573A1 (en) | 2013-09-12 |
| GT201400191A (es) | 2017-07-03 |
| KR20140136982A (ko) | 2014-12-01 |
| PH12014501997A1 (en) | 2014-11-24 |
| CN104519878A (zh) | 2015-04-15 |
| WO2013138322A1 (en) | 2013-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002406A1 (es) | Metodo para el tratamiento de la depresion refractaria o resistente al taratamiento que comprende administrar esketamina por via intravenosa o intranasal sola o en combinacion con uno o mas antidepresivos; composicion farmaceutica; y su uso en el tratamiento de la depresion refractaria o resistente al tratamiento. | |
| CL2013001410A1 (es) | Variante polipeptidica de fgf21; multimero que la comprende; composicion farmaceutica que la comprende; y su uso para tratar uno o mas trastornos asociados a fgf21. | |
| CL2012002606A1 (es) | Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales. | |
| CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
| CL2014001994A1 (es) | Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido. | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| CL2015001207A1 (es) | Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición. | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
| CL2015002860A1 (es) | Antagonistas de la alfa-v-beta-6 integrina | |
| CL2014002919A1 (es) | Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo. | |
| BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| CL2013002125A1 (es) | Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia. | |
| CL2012003643A1 (es) | Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
| BR112014030406A8 (pt) | combinação de canabidiol fitocanabinoide com hipotermia terapêutica, e, uso de uma combinação | |
| CL2014002326A1 (es) | Combinacion que comprende benzodioxanos y uno o mas agentes activos y su uso en el tratamiento de enfermedades tales como ateroesclerosis e infarto al miocardio. | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
| EA201200484A1 (ru) | Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином | |
| BR112014021068A2 (pt) | Inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor |